K36 Therapeutics
Latest round
- Series B
Last raised
- Jun 2023
Total raised
- $100M
Investors
- 5
About K36 Therapeutics
K36 Therapeutics specializes in targeted cancer therapies, particularly KTX-1001, which focuses on treating multiple myeloma.K36 Therapeutics primarily focuses on the development of KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is known to be overexpressed in approximately 20% of multiple myeloma patients due to the t(4;14) translocation. KTX-1001 is designed to provide targeted therapy for patients suffering from this specific type of cancer, addressing the underlying biological mechanisms associated with MMSET overexpression. The product aims to serve a critical need in the oncology market by offering a therapeutic solution for individuals impacted by multiple myeloma, particularly those affected by the t(4;14) genetic aberration. While the company has not disclosed specific customer demographics, it is evident that their focus is on healthcare providers, oncologists, and clinical trial participants within the oncology sector.K36 Therapeutics operates on a revenue model that includes partnerships and collaborations with healthcare institutions and pharmaceutical companies, which facilitate clinical trials and the eventual commercialization of KTX-1001. The company is positioned in a B2B environment, engaging with hospitals, research organizations, and oncologists involved in the treatment of multiple myeloma. The transaction structure may involve agreements for exclusive licensing rights or co-development deals for KTX-1001. Potential pricing plans for KTX-1001 could reflect the premium nature of innovative cancer therapies, particularly as it targets a specific genetic anomaly, thus providing significant value to healthcare providers in managing complex cancer cases. K36 Therapeutics aims to further develop KTX-1001 and explore new markets, particularly focusing on regions in North America and Europe by targeting additional cancer indications.
Who invested in K36 Therapeutics
5 investors across 2 rounds
See all investors in K36 Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about K36 Therapeutics
Who invested in K36 Therapeutics?
K36 Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has K36 Therapeutics raised?
K36 Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did K36 Therapeutics last raise money?
K36 Therapeutics's most recent round on record is a Series B, in Jun 2023.
What does K36 Therapeutics do?
K36 Therapeutics specializes in targeted cancer therapies, particularly KTX-1001, which focuses on treating multiple myeloma.
Where is K36 Therapeutics headquartered?
K36 Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like K36 Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at K36 Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like K36 Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.